IPO filing research

BIOVENTRIX, INC.

Surgical & Medical Instruments & Apparatus

ipo amended Nasdaq Capital Market S-1/A

BIOVENTRIX, INC. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1/A on 2026-05-15. Current deal snapshot: exchange Nasdaq Capital Market.

Filing Timeline

SEC EDGAR

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

First tracked pre-IPO filing for this issuer.

Common Stock · Exchange Nasdaq Capital Market · Ticker BVXX · Warrants to purchase 5% of total shares sold, exercisable at the IPO price · Use of proceeds Proceeds to be used for general corporate purposes · Underwriters Benchmark, a StoneX Company

2026-05-15 · 0001493152-26-023752

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Common Stock · Exchange Nasdaq Capital Market · Ticker BVXX · Underwriters will receive warrants to purchase 5% of the shares sold in the offering at the IPO price. · Flags warrants · Underwriters Benchmark, a StoneX Company

BioVentrix, Inc. is conducting an initial public offering (IPO) of common stock, aiming to list on Nasdaq under the symbol BVXX. The company develops medical devices to restore left ventricular function in heart failure patients, with its lead product, the Revivent System, in a pivotal U.S. trial. The filing includes details on the IPO structure, underwriting terms, and risks related to regulatory approvals and clinical trial outcomes.

2026-03-18 · 0001493152-26-010642

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common Stock · Exchange Nasdaq Capital Market · Ticker BVXX · Warrant to purchase 5% of the shares sold in the offering at the initial public offering price · Underwriters Benchmark, a StoneX Company

BioVentrix, Inc. is seeking to raise capital through its initial public offering (IPO) of common stock, aiming to commercialize its Revivent System for treating heart failure patients with reduced ejection fraction (HFrEF). The company's lead device, approved in Europe and in pivotal trials in the U.S., uses a minimally invasive procedure to restore left ventricular function. The IPO includes underwriting details, risk factors related to clinical trials and regulatory approvals, and plans for listing on Nasdaq. The filing highlights the company's focus on addressing high mortality rates in HFrEF patients under current standards of care.

2026-02-12 · 0001493152-26-006407

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

BioVentrix, Inc. is a medical device company focused on developing the Revivent System, a device for restoring left ventricular function in heart failure patients with reduced ejection fraction (HFrEF). The company is conducting a pivotal trial in the U.S. for the Revivent System, which has a CE mark in Europe. The current filing outlines an initial public offering (IPO) of common stock, with an assumed offering price and plans to list on Nasdaq under the symbol BVXX. The company also owns rights to Alginate, a hydrogel-based device for HFrEF patients without anterior scarring. The IPO includes underwriting terms, including a 7% discount and a warrant for underwriters.

2025-12-12 · 0001493152-25-027406

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

BioVentrix, Inc. is a medical device company developing proprietary devices to restore left ventricular function in heart failure patients with reduced ejection fraction (HFrEF). Its lead product, the Revivent System, has a CE mark in Europe and is in pivotal trials in the U.S., while it also owns rights to Alginate, a hydrogel-based treatment. The company is conducting an initial public offering (IPO) of common stock, with an assumed price range and plans to list on Nasdaq under the symbol BVXX. The offering includes underwriting discounts, a warrant for underwriters, and an over-allotment option.

2025-10-06 · 0001493152-25-016953

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

BIOVENTRIX, INC. is conducting an initial public offering (IPO) of common stock, seeking to list on Nasdaq under the symbol BVXX. The company develops medical devices to restore left ventricular function in heart failure patients, with its Revivent System currently in a pivotal FDA-approved trial (RELIVE Trial). The filing highlights risks related to clinical trial outcomes, regulatory approvals, and market uncertainties. As an emerging growth company, it may utilize reduced reporting requirements.

2025-08-05 · 0001641172-25-022123

Comparable Deals

5 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 5 using nearest neighbors.

+29.4%

Median day-1

60%

Above issue

+42.8%

Median week-1

-21.7%

Downside (p10)

Mobia Medical, Inc. MOBI

2026-05-08 $140M Day 1: -21.7% Wk 1: -19.7%

same SICrecent IPO

MiniMed Group, Inc. MMED

2026-03-06 $560M Day 1: -7.6% Wk 1: -17.3%

same SICrecent IPO

SpyGlass Pharma, Inc. SGP

2026-02-06 $150M Day 1: +65.0% Wk 1: +71.9%

same SICrecent IPO

Alamar Biosciences, Inc. ALMR

2026-04-17 $191M Day 1: +29.4% Wk 1: +42.8%

same SIC grouprecent IPO

Ceribell, Inc. CBLL

2024-10-11 $180M Day 1: +47.1% Wk 1: +55.9%

same SIC groupolder IPO

Recent News

BioVentrix, Inc. Announces German Reimbursement Designation

tennessean.com · 2026-03-26T04:33:00.000Z